Key result
Osimertinib binds seven cardiopulmonary toxicity hub targets in silico, showing stable HDAC1 and CREBBP affinity.
Why the study?
Osimertinib, a first-line therapy for EGFR T790M mutation-positive non-small cell lung cancer, is limited by significant cardiotoxicity and pulmotoxicity. The shared molecular pathogenesis underlying these concurrent adverse effects remains unclear.
This computational study proposes that osimertinib-induced cardiopulmonary toxicity may be driven by disruption of the CREBBP/EP300-HDAC1/HDAC2 epigenetic balance and interactions with TP53, ESR1, and SMARCA4, offering a theoretical basis for future experimental validation.
Answers are grounded in this paper and cite their sources.
Provides theoretical targets for osimertinib toxicity research; leaves open whether they drive clinical cardiopulmonary effects.
Context: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is first-line therapy for EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). However, its clinical utility is severely limited by significant cardiotoxicity and pulmotoxicity, which compromise treatment adherence and patient survival. The shared molecular pathogenesis underlying these concurrent adverse effects remains unclear and warrants systematic investigation. Methods We employed an integrated computational framework combining network toxicology, molecular docking, and molecular dynamics (MD) simulations. Multi-database screening identified 119 shared targets between osimertinib and cardiopulmonary toxicity, from which seven hub targets—TP53, ESR1, HDAC1, CREBBP, EP300, HDAC2, and SMARCA4—were prioritized. Enrichment analysis implicated these targets in epigenetic regulation and cancer-related pathways such as microRNAs in cancer. Molecular docking confirmed high-affinity binding of osimertinib to all hub targets (binding free energies − 6.4 to -7.2 kcal/mol). MD simulations demonstrated stable binding with HDAC1 and CREBBP (-20.85 and − 22.92 kcal/mol, respectively) and identified key interacting residues. This work outlines a multi-target, multi-pathway regulatory network and proposes an epigenetics-centered hypothesis: osimertinib-induced cardiopulmonary toxicity may arise from disruption of the CREBBP/EP300-HDAC1/HDAC2 epigenetic balance together with TP53-, ESR1-, and SMARCA4-mediated interactions, providing a theoretical basis for future experimental validation and therapeutic modulation.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied Osimertinib-induced cardiopulmonary toxicity. Osimertinib was evaluated on Binding free energy and stability of osimertinib with hub targets (HDAC1 and CREBBP). Osimertinib exhibited high-affinity binding to seven cardiopulmonary toxicity hub targets and stable binding with HDAC1 and CREBBP in molecular dynamics simulations.
Synapse has enriched 10 related papers. Consider them for comparative context: